Ligand ID: X89 Drugbank ID: DB01110(Miconazole) Indication:For topical application in the treatment of tinea pedis (athlete’s foot), tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum, in the treatment of cutaneous candidiasis (moniliasis), and in the treatment of tinea versicolor. |
DrReposER ID / Desc. | Hit PDBID |
Hit Macromolecule |
Res. Matches |
View | Interface | RMSD | Seq. Identity (%) |
HETATM | Dock | |
---|---|---|---|---|---|---|---|---|---|---|
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | ALA A 206LEU A 208LEU A 271ALA A 285LEU A 286 | 1.34A | 15.61 | None | ||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | ALA A 234VAL A 204LEU A 250ALA A 210TYR A 209 | 1.42A | 15.61 | None | ||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | ALA A 234LEU A 242LEU A 250TYR A 209LEU A 208 | 1.71A | 15.61 | None | ||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | ILE A 249LEU A 250VAL A 261LEU A 242ALA A 266 | 1.78A | 15.61 | None | ||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6lxt | SPIKE PROTEIN S2,SPIKE PROTEIN S2 (SARS-CoV-2) | 5 / 12 | ILE C 934ALA C1190LEU C 938LEU B 938LEU B 945 | 1.47A | 18.14 | None | ||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6lxt | SPIKE PROTEIN S2,SPIKE PROTEIN S2 (SARS-CoV-2) | 5 / 12 | ILE D 934ALA D1190LEU D 938LEU F 938LEU F 945 | 1.41A | 18.14 | None | ||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6lxt | SPIKE PROTEIN S2,SPIKE PROTEIN S2 (SARS-CoV-2) | 5 / 12 | ILE A 934ALA A1190LEU A 938LEU C 938LEU C 945 | 1.48A | 18.14 | None | ||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6lxt | SPIKE PROTEIN S2 (SARS-CoV-2) | 6 / 12 | ILE D 934ALA D1190LEU D 938LEU F 938ALA F 944LEU F 945 | 1.39A | 18.14 | None | ||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6lxt | SPIKE PROTEIN S2,SPIKE PROTEIN S2 (SARS-CoV-2) | 5 / 12 | ILE B 934ALA B1190LEU B 938LEU A 938LEU A 945 | 1.44A | 18.14 | None | ||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6lze | VIRAL PROTEASE (SARS-CoV-2) | 5 / 12 | ALA A 234VAL A 204LEU A 250ALA A 210TYR A 209 | 1.45A | 20.14 | None | ||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6lze | VIRAL PROTEASE (SARS-CoV-2) | 5 / 12 | ALA A 206LEU A 208LEU A 271ALA A 285LEU A 286 | 1.52A | 20.14 | None | ||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6m0k | VIRAL PROTEASE (SARS-CoV-2) | 5 / 12 | ALA A 234VAL A 204LEU A 250ALA A 210TYR A 209 | 1.44A | 20.14 | None | ||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6m0k | VIRAL PROTEASE (SARS-CoV-2) | 5 / 12 | ALA A 206LEU A 208LEU A 271ALA A 285LEU A 286 | 1.51A | 20.14 | None | ||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | ALA C 234LEU C 250ALA C 210TYR C 209LEU C 208 | 1.52A | 19.53 | None | ||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | ALA C 206LEU C 208LEU C 271ALA C 285LEU C 286 | 1.57A | 19.53 | None | ||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | ALA D 206LEU D 208LEU D 271ALA D 285LEU D 286 | 1.51A | 19.53 | None | ||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | ALA A 206LEU A 208LEU A 271ALA A 285LEU A 286 | 1.59A | 19.53 | None | ||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | ALA C 234VAL C 204LEU C 250ALA C 210TYR C 209 | 1.36A | 19.53 | None | ||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | ALA B 206LEU B 208LEU B 271ALA B 285LEU B 286 | 1.39A | 19.53 | None | ||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6m2q | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | ALA A 234VAL A 204LEU A 250ALA A 210TYR A 209 | 1.45A | 19.53 | None | ||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6m2q | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | ALA A 206LEU A 208LEU A 271ALA A 285LEU A 286 | 1.32A | 19.53 | None | ||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6m71 | NSP12NSP8 (SARS-CoV-2) | 5 / 12 | TYR A 346ALA A 382LEU A 329ALA B 110LEU A 271 | 1.51A | 17.30 | None | ||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 12 | ILE A 171TYR A 156ALA A 176LEU A 142LEU A 212 | 1.68A | 17.30 | None | ||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6m71 | NSP7NSP8 (SARS-CoV-2) | 5 / 12 | ILE C 68ALA C 65VAL C 16LEU D 95LEU C 55 | 1.56A | 10.95 | None | ||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6m71 | NSP7 (SARS-CoV-2) | 5 / 12 | ALA C 30LEU C 28VAL C 22ALA C 65LEU C 59 | 1.61A | 10.95 | None | ||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 12 | PHE A 45TYR A 129ALA A 706LEU A 708LEU A 240 | 1.67A | 17.30 | None | ||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6vxs | NSP3 (SARS-CoV-2) | 5 / 12 | PHE A 168VAL A 147HIS A 138ALA A 124LEU A 127 | 1.54A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6vxs | NSP3 (SARS-CoV-2) | 5 / 12 | PHE A 168VAL A 147LEU A 140ALA A 124LEU A 127 | 1.59A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6vxs | NSP3 (SARS-CoV-2) | 5 / 12 | PHE B 116TYR B 113ALA B 129VAL B 49ALA B 27 | 1.56A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6vxs | NSP3 (SARS-CoV-2) | 5 / 12 | PHE A 116TYR A 113ALA A 129VAL A 49ALA A 27 | 1.59A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6vxs | NSP3 (SARS-CoV-2) | 5 / 12 | PHE B 168VAL B 147HIS B 138ALA B 124LEU B 127 | 1.55A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6vxs | NSP3 (SARS-CoV-2) | 5 / 12 | ALA B 50LEU B 53VAL B 24LEU B 123ALA B 21 | 1.66A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | ILE A6951PHE A6954ALA A6966ALA A6905LEU A6893 | 1.38A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6w61 | 2'-O-METHYLTRANSFERASENSP10 (SARS-CoV-2) | 5 / 12 | PHE B4321VAL A6882HIS B4301ALA A6843LEU A7042 | 1.74A | 16.43 | None | ||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6w63 | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | ALA A 234VAL A 204LEU A 250ALA A 210TYR A 209 | 1.39A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6w63 | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | ALA A 206LEU A 208LEU A 271ALA A 285LEU A 286 | 1.55A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | LEU B 160VAL B 155HIS B 138ALA B 38LEU B 127 | 1.78A | 18.09 | NoneNoneNoneMES B 201 ( 3.4A)None | ||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | LEU A 160VAL A 155HIS A 138ALA A 38LEU A 127 | 1.70A | 18.09 | NoneAMP A 201 ( 4.4A)NoneAMP A 201 ( 3.9A)None | ||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | PHE A 168VAL A 155LEU A 140ALA A 129LEU A 127 | 1.73A | 18.09 | NoneAMP A 201 ( 4.4A)NoneAMP A 201 ( 3.4A)None | ||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | PHE B 116TYR B 113ALA B 129VAL B 49ALA B 27 | 1.58A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | ILE B 18PHE B 168LEU B 153ALA B 134LEU B 109 | 1.56A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | PHE B 168VAL B 147HIS B 138ALA B 124LEU B 127 | 1.78A | 18.09 | None | ||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | PHE A 116TYR A 113ALA A 129VAL A 49ALA A 27 | 1.56A | NoneNoneAMP A 201 ( 3.4A)AMP A 201 ( 3.7A)None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | PHE B 168VAL B 155LEU B 140ALA B 129LEU B 127 | 1.74A | 18.09 | None | ||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 12 | ILE C6951PHE C6954ALA C6966ALA C6905LEU C6893 | 1.49A | 18.77 | None | ||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6w75 | NSP10NSP16 (SARS-CoV-2) | 5 / 12 | PHE B4321VAL A6882HIS B4301ALA A6843LEU A7042 | 1.76A | 17.00 | None | ||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6w75 | NSP10NSP16 (SARS-CoV-2) | 5 / 12 | PHE D4321VAL C6882HIS D4301ALA C6843LEU C7042 | 1.75A | 17.00 | None | ||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 12 | ALA B 153LEU B 152ALA B 114TYR B 95LEU B 117 | 1.69A | NoneNone CL B 502 ( 3.8A)NoneNone | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6w9q | 3C-LIKE PROTEINASEPEPTIDE, NSP9 FUSION (SARS-CoV-2) | 5 / 12 | ALA A 107LEU A 106VAL A 102LEU A 45TYR A 89 | 1.49A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6wcf | NSP3 (SARS-CoV-2) | 5 / 12 | PHE A 168VAL A 147LEU A 140ALA A 124LEU A 127 | 1.54A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6wcf | NSP3 (SARS-CoV-2) | 5 / 12 | PHE A 168VAL A 147HIS A 138ALA A 124LEU A 127 | 1.56A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6wcf | NSP3 (SARS-CoV-2) | 5 / 12 | PHE A 116TYR A 113ALA A 129VAL A 49ALA A 27 | 1.54A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6wen | NSP3 (SARS-CoV-2) | 5 / 12 | PHE A 116TYR A 113ALA A 129VAL A 49ALA A 27 | 1.51A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6wey | NSP3 (SARS-CoV-2) | 5 / 12 | PHE A 320TYR A 317ALA A 333VAL A 253ALA A 231 | 1.43A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6wiq | NSP7 (SARS-CoV-2) | 5 / 12 | ALA A 30LEU A 28VAL A 22ALA A 65LEU A 59 | 1.55A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6wiq | NSP7NSP8 (SARS-CoV-2) | 5 / 12 | ILE A 68ALA A 65VAL A 16LEU B 95LEU A 55 | 1.52A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | ILE C6951PHE C6954ALA C6966ALA C6905LEU C6893 | 1.46A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6wkq | NSP16 (SARS-CoV-2) | 5 / 12 | ILE C6951PHE C6954ALA C6966ALA C6905LEU C6893 | 1.46A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6wnp | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | ALA A 234LEU A 250ALA A 210TYR A 209LEU A 208 | 1.50A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6wnp | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | ALA A 206LEU A 208LEU A 271ALA A 285LEU A 286 | 1.55A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6wnp | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | ALA A 234VAL A 204LEU A 250ALA A 210TYR A 209 | 1.43A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | PHE B 116TYR B 113ALA B 129VAL B 49ALA B 27 | 1.62A | NoneNoneAPR B 201 (-3.7A)APR B 201 (-3.7A)None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | PHE D 116TYR D 113ALA D 129VAL D 49ALA D 27 | 1.63A | NoneNoneAPR D 201 (-3.7A)APR D 201 (-3.6A)None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | PHE C 116TYR C 113ALA C 129VAL C 49ALA C 27 | 1.62A | NoneNoneAPR C 201 (-3.7A)APR C 201 (-3.8A)None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | PHE A 116TYR A 113ALA A 129VAL A 49ALA A 27 | 1.61A | NoneNoneAPR A 201 (-3.7A)APR A 201 (-3.8A)None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6wq3 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | ILE A6951PHE A6954ALA A6966ALA A6905LEU A6893 | 1.36A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6wqd | NSP7 (SARS-CoV-2) | 5 / 12 | ALA A 30LEU A 28VAL A 22ALA A 65LEU A 59 | 1.63A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6wqd | NSP7 (SARS-CoV-2) | 5 / 12 | ALA C 30LEU C 28VAL C 22ALA C 65LEU C 59 | 1.58A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6wqf | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | ALA A 206LEU A 208LEU A 271ALA A 285LEU A 286 | 1.54A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6wxd | NSP9 (SARS-CoV-2) | 5 / 12 | ALA B 108LEU B 106VAL B 102LEU A 4LEU A 97 | 1.37A | 15.63 | None | ||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6y2g | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | ALA B 206LEU B 208LEU B 271ALA B 285LEU B 286 | 1.30A | 19.53 | None | ||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | ILE A 249LEU A 250VAL A 261LEU A 242ALA A 266 | 1.78A | 15.85 | None | ||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | ALA A 206LEU A 208LEU A 271ALA A 285LEU A 286 | 1.34A | 15.85 | None | ||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | ALA A 234LEU A 242LEU A 250TYR A 209LEU A 208 | 1.71A | 15.85 | None | ||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | PHE A 219LEU A 282LEU A 208TYR A 209LEU A 253 | 1.76A | 15.85 | None | ||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 5 / 12 | LEU A 55VAL A 58LEU B 91ALA A 65LEU A 20 | 1.69A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 5 / 12 | ALA A 30LEU A 28VAL A 22ALA A 65LEU A 59 | 1.50A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 5 / 12 | ILE B 107ALA B 110VAL A 66LEU B 91LEU A 20 | 1.60A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 5 / 12 | ALA C 30LEU C 28VAL C 22ALA C 65LEU C 59 | 1.60A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6ynq | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | ALA A 206LEU A 208LEU A 271ALA A 285LEU A 286 | 1.34A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6ynq | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | ALA A 234VAL A 204LEU A 250ALA A 210TYR A 209 | 1.42A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6yt8 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | ALA A 206LEU A 208LEU A 271ALA A 285LEU A 286 | 1.35A | NoneNoneNoneNonePEG A 404 ( 3.6A) | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | PHE C 116TYR C 113ALA C 129VAL C 49ALA C 27 | 1.52A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | PHE A 116TYR A 113ALA A 129VAL A 49ALA A 27 | 1.52A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | PHE B 116TYR B 113ALA B 129VAL B 49ALA B 27 | 1.54A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | PHE E 116TYR E 113ALA E 129VAL E 49ALA E 27 | 1.56A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | ILE A 23ALA A 124LEU A 123HIS A 94LEU A 88 | 1.69A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | PHE D 116TYR D 113ALA D 129VAL D 49ALA D 27 | 1.50A | NoneNoneEDO D 205 (-4.5A)EDO D 209 (-4.6A)None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | PHE D 116TYR D 113ALA D 129VAL D 49ALA D 27 | 1.60A | NoneNoneAPR D 201 (-3.4A)APR D 201 (-3.7A)None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | PHE A 116TYR A 113ALA A 129VAL A 49ALA A 27 | 1.59A | NoneNoneAPR A 201 ( 3.7A)APR A 201 (-3.7A)None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | PHE C 116TYR C 113ALA C 129VAL C 49ALA C 27 | 1.59A | NoneNoneAPR C 201 (-3.6A)APR C 201 (-3.6A)None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | PHE E 116TYR E 113ALA E 129VAL E 49ALA E 27 | 1.59A | NoneNoneAPR E 201 (-3.5A)APR E 201 (-3.7A)None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | PHE B 116TYR B 113ALA B 129VAL B 49ALA B 27 | 1.58A | NoneNoneAPR B 201 (-3.6A)APR B 201 (-3.7A)None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | PHE A 116TYR A 113ALA A 129VAL A 49ALA A 27 | 1.58A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | PHE C 116TYR C 113ALA C 129VAL C 49ALA C 27 | 1.56A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | ILE B 18PHE B 168LEU B 153ALA B 134LEU B 109 | 1.68A | NoneNoneNoneEDO B 204 (-3.8A)None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | ILE A 18PHE A 168LEU A 153ALA A 134LEU A 109 | 1.63A | NoneNoneNoneEDO A 205 (-4.0A)None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | PHE B 116TYR B 113ALA B 129VAL B 49ALA B 27 | 1.53A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 7bqy | MAIN PROTEASE (SARS-CoV-2) | 5 / 12 | ALA A 206LEU A 208LEU A 271ALA A 285LEU A 286 | 1.55A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 7bqy | MAIN PROTEASE (SARS-CoV-2) | 5 / 12 | ALA A 234VAL A 204LEU A 250ALA A 210TYR A 209 | 1.41A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 7btf | NSP12 (SARS-CoV-2) | 5 / 12 | PHE A 528ALA A 685VAL A 662ALA A 656LEU A 655 | 1.65A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 7btf | NSP12 (SARS-CoV-2) | 5 / 12 | PHE A 45TYR A 129ALA A 706LEU A 708LEU A 240 | 1.61A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 7btf | NSP12NSP8 (SARS-CoV-2) | 5 / 12 | TYR A 346ALA A 382LEU A 329ALA B 110LEU A 271 | 1.51A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 7btf | NSP7NSP8 (SARS-CoV-2) | 5 / 12 | ILE D 107ALA D 110VAL C 66LEU D 91LEU C 20 | 1.43A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 7btf | NSP12 (SARS-CoV-2) | 5 / 12 | ILE A 632ALA A 656VAL A 662HIS A 642ALA A 685 | 1.62A | NoneNoneNone ZN A1002 (-3.3A)None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 7btf | NSP12 (SARS-CoV-2) | 5 / 12 | ILE A 171TYR A 156ALA A 176LEU A 142LEU A 212 | 1.66A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 7btf | NSP7 (SARS-CoV-2) | 5 / 12 | ALA C 30LEU C 28VAL C 22ALA C 65LEU C 59 | 1.65A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 7btf | NSP12 (SARS-CoV-2) | 5 / 12 | ALA A 685VAL A 662HIS A 642ALA A 656LEU A 655 | 1.55A | NoneNone ZN A1002 (-3.3A)NoneNone | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 7btf | NSP7NSP8 (SARS-CoV-2) | 5 / 12 | LEU C 55VAL C 58LEU D 91ALA C 65LEU C 20 | 1.64A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 7buy | VIRUS MAIN PROTEASE (SARS-CoV-2) | 5 / 12 | ALA A 234VAL A 204LEU A 250ALA A 210TYR A 209 | 1.43A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 7buy | VIRUS MAIN PROTEASE (SARS-CoV-2) | 5 / 12 | ALA A 206LEU A 208LEU A 271ALA A 285LEU A 286 | 1.52A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 12 | PHE A 45TYR A 129ALA A 706LEU A 708LEU A 240 | 1.64A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 12 | ILE A 632ALA A 656VAL A 662HIS A 642ALA A 685 | 1.63A | NoneNoneNone ZN A1002 (-3.1A)None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 12 | ILE A 171TYR A 156ALA A 176LEU A 142LEU A 212 | 1.70A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 12 | ILE A 145LEU A 212LEU A 178ALA A 250LEU A 245 | 1.69A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 7bv1 | NSP12NSP8 (SARS-CoV-2) | 5 / 12 | TYR A 346ALA A 382LEU A 329ALA B 110LEU A 271 | 1.52A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 12 | ALA A 685VAL A 662HIS A 642ALA A 656LEU A 655 | 1.58A | NoneNone ZN A1002 (-3.1A)NoneNone | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 12 | PHE A 528ALA A 685VAL A 662ALA A 656LEU A 655 | 1.64A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 7bv2 | NSP12 (SARS-CoV-2) | 5 / 12 | ILE A 171TYR A 156ALA A 176LEU A 142LEU A 212 | 1.68A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 7bv2 | NSP12 (SARS-CoV-2) | 5 / 12 | ALA A 685VAL A 662HIS A 642ALA A 656LEU A 655 | 1.63A | A T 11 ( 4.7A)None ZN A1002 (-3.2A)NoneNone | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 7bv2 | NSP12 (SARS-CoV-2) | 5 / 12 | PHE A 348TYR A 346LEU A 663LEU A 351LEU A 636 | 1.69A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 7bv2 | NSP12NSP8 (SARS-CoV-2) | 5 / 12 | TYR A 346ALA A 382LEU A 329ALA B 110LEU A 271 | 1.48A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 7bv2 | NSP12 (SARS-CoV-2) | 5 / 12 | PHE A 45TYR A 129ALA A 706LEU A 708LEU A 240 | 1.66A | None | |||
![]() | 3OZU_A_X89A411_1 (FLAVOHEMOPROTEIN) | 7bv2 | NSP12 (SARS-CoV-2) | 5 / 12 | ILE A 145LEU A 212LEU A 178ALA A 250LEU A 245 | 1.68A | None |